Liver Hepatocellular Carcinoma / LIHC (TCGA)

Overview

LIHC is the TCGA cohort identifier for liver hepatocellular carcinoma. The corresponding OncoTree code is HCC (Hepatocellular Carcinoma). LIHC encompasses hepatocellular carcinoma broadly, including the rare fibrolamellar carcinoma (FLC) subtype. This page covers findings specifically attributed to the TCGA LIHC cohort.

Cohorts in the corpus

  • TCGA LIHC cohort: included as one of 33 cancer types in the pan-cancer fusion landscape study; subset of the PanCancer Atlas (lihc_tcga_pan_can_atlas_2018).

Recurrent alterations

  • Pan-cancer fusion study (9,624 TCGA samples) identified DNAJB1–PRKACA as a liver-only fusion specific to the fibrolamellar carcinoma (FLC) subtype of LIHC, corroborating Dinh et al. 2017; WNK1/WNK2 fusions also detected in LIHC without matching copy-number amplification PMID:29617662.

Subtypes

  • Fibrolamellar carcinoma (FLC): characterized by the pathognomonic DNAJB1–PRKACA fusion; clinically distinct from conventional HCC (younger patients, lacking cirrhosis). See FLC.
  • Conventional HCC: driven by viral hepatitis (HBV/HCV), alcohol, NASH; major drivers include TP53, CTNNB1, TERT.

Therapeutic landscape

No drug-specific findings for LIHC reported in the current corpus beyond general HCC treatment considerations.

Sources

  • PMID:29617662 — Pan-cancer fusion landscape (Gao et al., 2018)

This page was processed by crosslinker on 2026-05-15.